Robertson Lab

Dr. Gregory Robertson’s research is focused on the field of Mycobacterium tuberculosis host-pathogen interactions with emphasis on the development of novel preclinical tools, use of TB mouse models for drug evaluation, and evaluation of drug activity and resistance in vitro and in vivo. He also leads preclinical animal studies as part of the Consortium for Applied Microbial Metrics including other investigators from the University of California San Francisco, Denver VA Medical Center, and CU Anschutz Medical Campus.

We are looking for talented researchers to join our team!

Contact to Join Our Team

research project

TB Drug Accelerator

Goal: (i) To identify in vivo active compounds, (ii) to enable more effective hit-to-lead and lead optimization cycles, and (iii) to support the selection of pre-clinical candidates as a service for the TB Drug Accelerator researchers.

view project
research project

Development of Novel Proteins Synthesis Inhibitors for MDR Tuberculosis

Goal: This proposal seeks to continue the development of the spectinamides as combination agents for MDR-TB, with a focus on their utility to treat chronic infections and as tools to understand the role of native efflux in tuberculosis drug persistence.

research project


Goal: Tuberculosis is difficult to treat because many drugs are hindered in their ability to penetrate tissues that harbor the pathogen. We propose to overcome this problem by developing new technology based on peptides that recognize and home to TB-infected tissue as a means to target drug payloads to where they are needed most.

research project

NIAID/NIH funded UM1 cooperative agreement: PReclinical DesIgn and Clinical Translation of TB Regimens (PReDicTR) Consortium.

The core goal is to unite key scientists and dedicated stakeholders to build a translational research platform to accurately and efficiently identify and advance the most promising TB treatment regimens through the developmental pipeline into clinical trials.

research project

Validation of Mtb ribosomal RNA as a PD marker of treatment response

Goal: The primary output from this investment is the rapid and comprehensive characterization of novel RNA-based PD markers as measures of treatment-shortening potency.


A Modified BPaL Regimen for Tuberculosis Treatment replaces Linezolid with Inhaled Spectinamides.
Ali MZ, Dutt TS, MacNeill A, Walz A, Patterson J, Pearce C, Lam H, Henao-Tamayo M, Lee RE, Liu J, Robertson GT, Hickey AJ, Meibohm B, Gonzalez-Juarrero M.bioRxiv. 2023 Nov 16:2023.11.16.567434. doi: 10.1101/2023.11.16.567434. Preprint. PMID: 38014249

Use of multiple pharmacodynamic measures to deconstruct the Nix-TB regimen in a short-course murine model of tuberculosis.
Lyons MA, Obregon-Henao A, Ramey ME, Bauman AA, Pauly S, Rossmassler K, Reid J, Karger B, Walter ND, Robertson GT. Antimicrob Agents Chemother2024 Mar 19;:e0101023doi: 10.1128/aac.01010-23. Online ahead of print. PubMed PMID: 38501805.

Transcriptional adaptation of Mycobacterium tuberculosis that survives prolonged multi-drug treatment in mice.
Wynn EA, Dide-Agossou C, Reichlen M, Rossmassler K, Al Mubarak R, Reid JJ, Tabor ST, Born SEM, Ransom MR, Davidson RM, Walton KN, Benoit JB, Hoppers A, Loy DE, Bauman AA, Massoudi LM, Dolganov G, Strong M, Nahid P, Voskuil MI, Robertson GT, Moore CM, Walter ND.mBio. 2023 Oct 31;14(6):e0236323. doi: 10.1128/mbio.02363-23. Online ahead of print. PMID: 37905920

Drug distribution and efficacy of the DprE1 inhibitor BTZ-043 in the C3HeB/FeJ mouse tuberculosis model.
Ramey ME, Kaya F, Bauman AA, Massoudi LM, Sarathy JP, Zimmerman MD, Scott DWL, Job AM, Miller-Dawson JA, Podell BK, Lyons MA, Dartois V, Lenaerts AJ, Robertson GT. Antimicrob Agents Chemother. 2023 Nov 15;67(11):e0059723. doi: 10.1128/aac.00597-23. Epub 2023 Oct 4. PMID: 37791784

Lung microenvironments harbor Mycobacterium tuberculosis phenotypes with distinct treatment responses.
Walter ND, Ernest JP, Dide-Agossou C, Bauman AA, Ramey ME, Rossmassler K, Massoudi LM, Pauly S, Al Mubarak R, Voskuil MI, Kaya F, Sarathy JP, Zimmerman MD, Dartois V, Podell BK, Savic RM, Robertson GT. Antimicrob Agents Chemother. 2023 Aug 11:e0028423. doi: 10.1128/aac.00284-23. Online ahead of print. PMID:37565762

more publications


Gregory Robertson, Ph.D.

Lab Principal Investigator [PI]
Assistant Professor

Lisa Woolhiser, M.S.

Research Associate IV

Lisa Massoudi

Research Associate III

Allison Bauman

Research Associate III

Noalani Benedict, DVM

Research Associate II

Ashley Gerwing

Research Associate I

Leah Ortowski

Research Associate I

Madelyn Maclaughlin

Ph.D. Student/Graduate Research Assistant

Brenna Dowden

Student Researcher

Isabelle Johnson

Student Researcher

Sierra Johnson

Student Researcher

Tess Kilberg

Student Researcher

Avni Mirajkar

Student Researcher

Morgan Proud

Student Researcher

Joel Rushefsky

Student Researcher

Josie Small

Student Researcher

Ana Carolina Takutsa Fonseca

MARC student researcher

Eja Willis

Student Researcher

news and updates view all

contact information

Microbiology room B308

Microbiology room B331

(970) 491-3750